Price · as of 2026-09-04
$14.19
Market cap 200.82M
Price history
| Week | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 23, 2026 – Feb 27, 2026 | $14.58 | $15.93 | $13.06 | $14.75 | |
| Mar 2, 2026 – Mar 6, 2026 | $13.81 | $16.77 | $13.81 | $14.82 | 0 |
| Mar 9, 2026 – Mar 13, 2026 | $14.59 | $15.84 | $13.57 | $13.75 | 0 |
| Mar 16, 2026 – Mar 20, 2026 | $13.77 | $13.99 | $11.95 | $13.13 | 0 |
| Mar 23, 2026 – Mar 27, 2026 | $13.21 | $13.50 | $12.77 | $13.23 | 0 |
| Mar 30, 2026 – Apr 2, 2026 | $13.16 | $13.90 | $13.00 | $13.44 | 0 |
| Apr 6, 2026 – Apr 10, 2026 | $13.44 | $14.18 | $12.63 | $12.71 | 0 |
| Apr 13, 2026 – Apr 17, 2026 | $12.66 | $14.63 | $12.66 | $14.41 | 0 |
| Apr 20, 2026 – Apr 24, 2026 | $14.42 | $14.80 | $13.46 | $13.49 | 0 |
| Apr 27, 2026 – May 1, 2026 | $13.59 | $13.66 | $12.50 | $13.43 | 0 |
| May 4, 2026 – May 8, 2026 | $13.30 | $13.57 | $12.75 | $13.07 | 0 |
| May 11, 2026 – May 15, 2026 | $13.08 | $13.97 | $12.91 | $13.23 | 0 |
| May 18, 2026 – May 22, 2026 | $13.24 | $13.57 | $12.61 | $13.09 | 0 |
| May 25, 2026 – May 29, 2026 | $13.20 | $14.14 | $12.93 | $13.00 | 0 |
| Jun 1, 2026 – Jun 5, 2026 | $13.00 | $13.10 | $11.77 | $11.80 | 0 |
| Jun 8, 2026 – Jun 12, 2026 | $11.90 | $12.53 | $11.40 | $12.37 | 0 |
| Jun 15, 2026 – Jun 18, 2026 | $12.40 | $12.96 | $12.20 | $12.66 | 0 |
| Jun 22, 2026 – Jun 26, 2026 | $12.65 | $13.20 | $12.59 | $13.19 | 0 |
| Jun 29, 2026 – Jul 2, 2026 | $13.20 | $13.80 | $13.20 | $13.65 | 0 |
| Jul 6, 2026 – Jul 10, 2026 | $13.60 | $13.61 | $12.20 | $12.46 | 0 |
| Jul 13, 2026 – Jul 17, 2026 | $12.40 | $12.59 | $11.93 | $12.15 | 0 |
| Jul 20, 2026 – Jul 24, 2026 | $12.14 | $12.35 | $11.48 | $11.49 | 0 |
| Jul 27, 2026 – Jul 31, 2026 | $11.61 | $11.80 | $11.13 | $11.35 | 0 |
| Aug 3, 2026 – Aug 7, 2026 | $11.45 | $12.49 | $11.30 | $12.34 | 0 |
| Aug 10, 2026 – Aug 14, 2026 | $12.25 | $12.97 | $12.03 | $12.84 | 0 |
| Aug 17, 2026 – Aug 21, 2026 | $12.78 | $13.88 | $12.72 | $13.20 | 0 |
| Aug 24, 2026 – Aug 28, 2026 | $13.27 | $14.09 | $13.04 | $13.64 | 0 |
| Aug 31, 2026 – Sep 4, 2026 | $13.53 | $14.68 | $13.10 | $14.19 | 0 |
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | $9.65 | -32% |
| P/E | -4.75 | |
| P/B | 1.14 | |
| P/S | 12.64 | |
| EV/EBITDA | 0.41 | |
| PEG | — | |
| P/TBV | 1.14 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | |||||
| 2025 | $13.75 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
- CEO
- Kathleen Gallagher
- Employees
- 511
- Beta
- 0.37
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RNA | Atrium Therapeutics, Inc. | $12.34 | 200.82M | $9.65 | -22% | -4.75 | 1.14 | 12.64 | 0.41 | — | 1.14 | 100.00% | -412.58% | -411.88% | — | — | — | 0.02 | — | 6.53 | 6.46 | 3.48 | — | — | — | -18.09% | -0.98 | — | 0.00% | 0.00% | 0.00% | 0.40 | 0.73 | -1.67 | 2.14 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9.65 ÷ $14.19) − 1 = -31.99% (IC, example).